{"groups":[{"description":"Participants with 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"FG000","title":"1q21 Amplified"},{"description":"Participants without 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"FG001","title":"1q21 Not Amplified"},{"description":"Participants who failed 1q21 test/had missing results for 1q21 test. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"FG002","title":"Failed/Missing Test"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Patient choice"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Death"}],"milestones":[{"achievements":[{"comment":"Received allocated treatment","groupId":"FG000","numSubjects":"26"},{"comment":"Received allocated treatment","groupId":"FG001","numSubjects":"72"},{"comment":"Received allocated treatment","groupId":"FG002","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"comment":"Completed PAD induction","groupId":"FG000","numSubjects":"21"},{"comment":"Completed PAD induction","groupId":"FG001","numSubjects":"68"},{"comment":"Completed PAD induction","groupId":"FG002","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Completed PAD Induction"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Patient choice"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Efficacy data unavailable"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Patient response missing"}],"milestones":[{"achievements":[{"comment":"Completed PAD induction","groupId":"FG000","numSubjects":"21"},{"comment":"Completed PAD induction","groupId":"FG001","numSubjects":"68"},{"comment":"Completed PAD induction","groupId":"FG002","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"comment":"participants analyzed","groupId":"FG000","numSubjects":"20"},{"comment":"participants analyzed","groupId":"FG001","numSubjects":"63"},{"comment":"participants analyzed","groupId":"FG002","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Primary Endpoint Analysis"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"comment":"Participants analyzed for primary endpoint","groupId":"FG000","numSubjects":"20"},{"comment":"Participants analyzed for primary endpoint","groupId":"FG001","numSubjects":"63"},{"comment":"Participants analyzed for primary endpoint","groupId":"FG002","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"comment":"Completed 3-month follow-up","groupId":"FG000","numSubjects":"20"},{"comment":"Completed 3-month follow-up","groupId":"FG001","numSubjects":"60"},{"comment":"Completed 3-month follow-up","groupId":"FG002","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Completed 3-month Follow up"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"Efficacy data unavailable"}],"milestones":[{"achievements":[{"comment":"Completed 3-month follow-up","groupId":"FG000","numSubjects":"20"},{"comment":"Completed 3-month follow-up","groupId":"FG001","numSubjects":"60"},{"comment":"Completed 3-month follow-up","groupId":"FG002","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"comment":"Participants analyzed for secondary endpoint","groupId":"FG000","numSubjects":"20"},{"comment":"Participants analyzed for secondary endpoint","groupId":"FG001","numSubjects":"58"},{"comment":"Participants analyzed for secondary endpoint","groupId":"FG002","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Secondary Endpoint Analysis"}],"preAssignmentDetails":"107 participants were enrolled and they all received the study treatment.","recruitmentDetails":"The participants were enrolled at multiple sites in Australia"}